WuXi XDC to acquire a 60% stake in BioDlink for HKD2.79bn.

Synopsis

WuXi XDC, a CRDMO provider that specializes in the research, development, and manufacturing of antibody‑drug conjugates, offered to acquire a 60% stake in BioDlink, a CDMO provider that specializes in the development and manufacturing of biologics, for HKD2.79bn.

Principals

target

Biodlink International Company

bidder

Wuxi Xdc Cayman

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context